As of October 2026, branded GLP-1s list at roughly $1,000 to $1,350 a month, but most people pay far less: $25 with covered commercial insurance and a savings card, $149 to $499 through manufacturer self-pay programs, or $50 through the Medicare GLP-1 Bridge. Coverage depends mainly on whether the drug is prescribed for diabetes or weight loss.
The number you see in a headline — “over $1,000 a month” — is a list price, and almost no one actually pays it. What a given person pays for a GLP-1 medication depends on a chain of intermediaries most patients never see: the manufacturer's list price, the rebates negotiated by pharmacy benefit managers, what an insurance plan chooses to cover, and the manufacturer's own savings card. Understanding where the money moves is the only way to make sense of why two people can pay wildly different amounts for the identical pen.
What is the difference between list price, net price and your price?
Three different prices coexist. The list price is the sticker the manufacturer sets. The net price is what the manufacturer actually collects after the confidential rebates it pays to PBMs and insurers to win formulary placement — often dramatically lower than list. And your price is your copay or coinsurance, which is governed by your specific plan's design. The reason the system feels opaque is that these three numbers are only loosely connected, and the rebate layer in the middle is deliberately not public.
What decides whether insurance covers a GLP-1?
The single biggest fork is indication. Plans far more readily cover a GLP-1 prescribed for type 2 diabetes than the same molecule prescribed purely for weight loss. That distinction is also why the policy debate has centered on Medicare. Federal law has long restricted Medicare Part D from covering drugs used for weight loss, so coverage there has traditionally hinged on a qualifying condition (such as diabetes, or an approved cardiovascular indication) rather than obesity alone. Analyses of expanding Medicare coverage to treat obesity project a substantial fiscal impact precisely because the eligible population is so large and the prices so high.[1] Ethicists and health-policy scholars have argued Medicare should cover these drugs — but explicitly conditioned on the prices coming down to affordable levels first.[2]
That restriction has now been partially, temporarily lifted. Starting July 1, 2026, CMS launched the Medicare GLP-1 Bridge, a demonstration that gives eligible Part D enrollees access to three GLP-1s prescribed to reduce and keep off excess weight — Wegovy (injection and tablets), the Zepbound KwikPen, and Foundayo — for a flat $50 copay per 28- or 30-day fill.[5] It runs through December 31, 2027 and sits outside standard Part D cost-sharing: the $50 does not count toward your Part D out-of-pocket total, and low-income subsidies do not apply to it.[6] Eligibility is narrower than “anyone with obesity.” You must be 18 or older and, when you start, have a BMI of at least 35; or at least 30 with heart failure with preserved ejection fraction, uncontrolled hypertension or stage 3a+ chronic kidney disease; or at least 27 with prediabetes, a prior heart attack or stroke, or symptomatic peripheral artery disease. People with type 2 diabetes, moderate-to-severe sleep apnea or MASH are excluded, because their GLP-1 is already coverable through their regular Part D plan; the single-dose Zepbound pen and Zepbound vials are not covered.[7] It is explicitly a temporary bridge, not a permanent change to what Part D plans must cover, and CMS has said the broader BALANCE Model will not launch in 2027,[5] so anyone on Medicare should confirm current eligibility directly.
Do savings cards and self-pay programs lower the cost?
For commercially insured patients, manufacturer savings cards can cut the monthly out-of-pocket cost sharply — but they come with fine print. They typically exclude anyone on a government plan like Medicare or Medicaid, they often require that your plan already provide some coverage, and the deepest discounts are usually time-limited. For the uninsured or those whose plan excludes the drug entirely, the cash route has become far cheaper than list. As of October 2026, Lilly sells Zepbound (vial or KwikPen) for $299–$449 a month by dose and Foundayo tablets from $149, and Novo sells the Wegovy pen for $349 ($199 for the first two months) and Wegovy tablets for $149–$299.[8] Novo has also announced it will cut the list price of Wegovy, Ozempic and Rybelsus to $675 a month on January 1, 2027, while saying its self-pay prices are unaffected.[9] Compounded alternatives are the other fallback, with their own trade-offs.
Why cost is a clinical variable, not just a financial one
Cost is not separate from outcomes — it directly shapes them, because these drugs only work while you keep taking them. Real-world studies of why people stop GLP-1 therapy find that cost and coverage loss are among the leading reasons for discontinuation, alongside side effects.[3]Since stopping the drug typically reverses much of the weight loss, an affordability gap is effectively a clinical failure point. Cost-effectiveness analyses comparing pharmacotherapy with behavioral and surgical options reinforce that the value calculation is highly sensitive to price — the drugs look very different at list price than at a discounted net price.[4] That pressure is also what drives people to stretch a vial: “microdosing” a GLP-1 is a trend rather than a protocol, and the honest problem with it is that efficacy is dose-related and no trial has tested intentional sub-therapeutic dosing.
The honest bottom line
What you pay for a GLP-1 is set less by the molecule than by your indication, your plan, and the invisible rebate machinery behind both. The practical checklist: confirm whether your plan covers the drug for your specific indication, check whether a manufacturer savings card applies to your coverage type, check whether the temporary Medicare GLP-1 Bridge applies if you're on Part D, and budget for continuity — because the most expensive outcome is starting, losing weight, and then being priced out of staying on it, including when a temporary program like the Bridge expires.